Hummingbird Diagnostics Overview
- Year Founded
-
1998
- Status
-
Private
- Employees
-
31
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$708K
- Investors
-
2
Hummingbird Diagnostics General Information
Description
Developer of novel miRNA-based blood-borne diagnostics intended for early disease detection of indications. The company's developed blood-based diagnostic tests for the selection of late-stage NSCLC patients most likely to benefit from immunotherapies to deliver immediate value and actionable clinical guidance, enabling healthcare providers to provide more tailored treatment to patients.
Contact Information
Website
www.hummingbird-diagnostics.comCorporate Office
- Im Neuenheimer Feld 583
- 69120 Heidelberg
- Germany
Corporate Office
- Im Neuenheimer Feld 583
- 69120 Heidelberg
- Germany
Hummingbird Diagnostics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Grant | 29-Apr-2020 | $708K | Completed | Generating Revenue | ||
| 7. Later Stage VC | 01-Jan-2016 | Completed | Generating Revenue | |||
| 6. Secondary Transaction - Private | 01-Jan-2007 | Completed | Generating Revenue | |||
| 5. Later Stage VC | 25-May-2005 | Completed | Generating Revenue | |||
| 4. Bankruptcy: Admin/Reorg | 11-Oct-2004 | Completed | Bankruptcy: Admin/Reorg | |||
| 3. Early Stage VC | 19-Nov-2002 | Completed | Startup | |||
| 2. Early Stage VC (Series B) | 26-Oct-2001 | $20M | $20M | Completed | Startup | |
| 1. Early Stage VC | Completed | Startup |
Hummingbird Diagnostics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Hummingbird Diagnostics Patents
Hummingbird Diagnostics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026131564-A1 | Predictive mirnas for response to lung cancer therapy | Pending | 17-Dec-2024 | ||
| WO-2026027540-A1 | Treating lung cancer by blocking a 28s ribosomal rna region | Pending | 30-Jul-2024 | ||
| WO-2025237620-A1 | A computational method for small rna biomarker modification classification | Pending | 16-May-2024 | ||
| WO-2025237619-A1 | Ribosomal rna fragment methylation pattern indicative for lung cancer | Pending | 16-May-2024 | ||
| EP-4824275-A1 | Small non-coding rna nanopore sequencing | Pending | 13-Dec-2023 | C12Q1/6806 |
Hummingbird Diagnostics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Hummingbird Diagnostics Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Alzheimers Drug Discovery Foundation | Not-For-Profit Venture Capital | |||
| GreyBird Ventures | Venture Capital | Minority |
Hummingbird Diagnostics FAQs
-
When was Hummingbird Diagnostics founded?
Hummingbird Diagnostics was founded in 1998.
-
Where is Hummingbird Diagnostics headquartered?
Hummingbird Diagnostics is headquartered in Heidelberg, Germany.
-
What is the size of Hummingbird Diagnostics?
Hummingbird Diagnostics has 31 total employees.
-
What industry is Hummingbird Diagnostics in?
Hummingbird Diagnostics’s primary industry is Diagnostic Equipment.
-
Is Hummingbird Diagnostics a private or public company?
Hummingbird Diagnostics is a Private company.
-
What is Hummingbird Diagnostics’s current revenue?
The current revenue for Hummingbird Diagnostics is .
-
How much funding has Hummingbird Diagnostics raised over time?
Hummingbird Diagnostics has raised $62.9M.
-
Who are Hummingbird Diagnostics’s investors?
Alzheimers Drug Discovery Foundation and GreyBird Ventures have invested in Hummingbird Diagnostics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
